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Abstract
Background: In independent studies, IBD, IBS and HCV have each been associated with a substantially increased
risk of psychological problems such as depression and anxiety and impairment of quality of life compared to the
general healthy population. However, the relative psychological burden for each of these diagnoses is unknown
as it has never been compared contemporaneously at one institution. Current local data are therefore needed to
enable an evidence-based allocation of limited clinical psychological resources.
Methods: Overall, 139 outpatients (64 IBD, 41 HCV, and 34 IBS) were enrolled in this cross-sectional study. The
HADS, SCL90, SF-12 and appropriate disease-specific activity measures were administered. Differences between
groups were assesed with ANOVA, the Chi-Square test and the independent samples t-test (two-tailed).
Results: Each of the three groups had significantly lower quality of life than the general population (p < 0.05).
Overall, a total of 58 (42%) participants met HADS screening criteria for anxiety and 26 (19%) participants for
depression. The HCV group had a significantly higher prevalence of depression than either of the other groups
(HCV = 34%, IBS = 15% and IBD = 11%, p = 0.009). In the SCL90, the three disease groups differed on 7 out of
12 subscales. On each of these subscales, the HCV group were most severely affected and differed most from the
general population.
Conclusion: Patients with these common chronic gastrointestinal diseases have significant impairment of quality
of life. Anxiety is a greater problem than depression, although patients with HCV in particular, should be regularly
monitored and treated for co-morbid depression. Evaluation of specific psychological interventions targeting
anxiety is warranted.
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Psychological co-morbidities are prevalent in patients
with chronic gastrointestinal and hepatologic disorders
[1]. However, securing clinical funding to target these
problems in a systematic fashion is difficult even though
psychological interventions may improve patients' out-
comes [2] and reduce health care utilisation [3]. There are
multiple conflicting demands for resources in clinical gas-
troenterology and traditionally each subspecialty area
within a unit has sought "special case" status. Therefore,
direct comparisons of psychological co-morbidity
between these common gastrological conditions within a
unit have not been previously performed. To fill this evi-
dence gap we thus sought to directly compare the preva-
lence of depression and anxiety disorders in three
common chronic gastroenterological disorders to provide
most up-to-date local data which enable more efficient,
evidence-based use of resources.
Inflammatory bowel disease (IBD), irritable bowel syn-
drome (IBS) and chronic hepatitis C (HCV) are chronic
diseases frequently encountered in gastroenterology. Even
though the conditions differ in their aetiology and symp-
toms, they all have been associated with an increased
prevalence of psychological co-morbidities in independ-
ent studies [4-6]. Despite studies of the co-occurrence of
IBS in IBD [7] as well IBD and HCV [8], there is little
research which directly compares quality of life and the
prevalence of psychological disorders between these three
diseases. Interestingly, common treatments for two of
these conditions are associated with mood disorders. This
is particularly so for interferon-alpha treatment in patients
with hepatitis C and corticosteroids in IBD. Thus, these
patients' depression and anxiety may in part be iatrogenic.
On the other hand, IBD and IBS commonly coexist and
although, traditionally, IBD is regarded as an inflamma-
tory disorder and IBS as a functional disorder, recently, it
has become increasingly difficult to make absolute dis-
tinctions between the two conditions, as current research
now provides evidence on the existence of inflammatory
abnormalities in the gut of patients with IBS [9,10]. Some-
what puzzlingly, IBS, which causes the least objectively
quantifiable disturbance to gastrointestinal function, has
been thought to have the highest prevalence of anxiety
and depression among these three conditions; however,
these data come from non-comparative studies [6,11].
Thus, the current study aims to determine whether real
differences exist among IBD, IBS and HCV with respect to
depression, anxiety and quality of life by comparing
patients recruited contemporaneously from a single site.
Methods
Participants and recruitment
Patients with clinically diagnosed (by gastroenterologists)
IBD, IBS and HCV were recruited to this study between
November 2005 and June 2006 through the Outpatient
Clinic at the Department of Gastroenterology and Hepa-
tology at the Royal Adelaide Hospital. Participants must
have had sufficient knowledge of English to understand
and answer the questionnaires. HCV patients with known
cirrhosis of the liver were excluded from the study. The
study was described to potential participants and each
participant was provided with a consent form, question-
naires and a reply paid envelope. Participants were asked
to complete a survey comprising a measure of anxiety and
depression; a measure of a broad psychological profile; a
measure of quality of life; and a measure of disease activ-
ity (in the HCV group, a blood test indicating active viral
replication was taken as a dichotomous variable for active
versus inactive disease).
Measurements
Anxiety and depression screening
Screening for anxiety and depression was conducted with
the Hospital Anxiety and Depression Scale (HADS). The
HADS contains 14 questions graded on a 4-point Likert
scale (0–3), with subscales of anxiety (seven items) and
depression (seven items), with a sum score ranging from
0 to 21 for each of anxiety and depression. A cut-off value
for clinical caseness is 7. Scores between 8 and 10 are
interpreted as possible cases, and = 11 as certain cases.
Importantly, the HADS is a screening measure and can
only be used to estimate a likely prevalence of anxiety and
depression, and not to establish a firm diagnosis. The lat-
ter can only be made by a psychologist or a psychiatrist
using a structured interview based on the DSM-IV [12].
Psychological profiles
Participants' broad psychological profiles were assessed
by the SCL-90-R Symptom Checklist-90-R (SCL-90). This
is a 90-item self-report instrument. The SCL-90 contains 9
subscales: Somatization, Obsessive-Compulsive, Depres-
sion, Anxiety, Hostility, Phobic Anxiety, Paranoid Idea-
tion, and Psychoticism. It also comprises three global
indices: Global Severity Index (GSI), Positive Symptom
Distress Index, and Positive Symptom Total [13]. There
are no specified cut-off values for this scale; however, case-
ness can be identified when the GSI score ≥ 63 (after the
transformation into the T score) or when any two primary
dimension scores are ≥ 63.
Quality of life
Screening for quality of life was performed with the Short
Form 12 Health Survey (SF-12). The SF-12 contains two
subscales: the Mental Component Summary (MCS) and
the Physical Component Summary (PCS) [14]. Scores for
each subscale range between 0 and 100, with increasing
values indicating better health.Page 2 of 8
(page number not for citation purposes)
Clinical Practice and Epidemiology in Mental Health 2008, 4:15 http://www.cpementalhealth.com/content/4/1/15Disease activity
Disease activity in IBD participants was assessed with the
Crohn's Disease Activity Index (CDAI) [15] or the Simple
Clinical Colitis Activity Index (SCCAI) [16] as appropri-
ate. A CDAI score ≤ 150 was considered remission in CD
and a SCCAI score of ≤ 2 was considered remission in UC.
The CDAI was measured via retrospective assessment of
symptoms.
Disease activity in IBS patients was measured by two ques-
tions added into the general health survey: "Have you got
satisfactory control of your IBS symptoms over the last 3
months?" and "Are you now feeling better or worse when
compared to your last visit in the clinic?". Answering "yes"
and "better" to these questions was considered remission
in IBS.
Disease activity in HCV (or, more precisely, ongoing viral
replication) was measured by RT-PCR HCVRNA. RT-PCR
HCVRNA "Not detected" was considered remission of
HCV. RT-PCR HCVRNA is a marker of an ongoing infec-
tion. Values for the presence of HCV RNA in the HCV
patients and heamatocrit in the IBD patients were rou-
tinely conducted by the treating physicians as per the
usual treatment schedule.
Ethical considerations
The study was approved by the Royal Adelaide Hospital
Research Ethics Committee. Participants were aware that
their care did not in any way depend on participation or
non-participation in the study. Each participant gave writ-
ten informed consent. The work was performed in accord-
ance with the principles of the 1983 Declaration of
Helsinki [17].
Statistical analysis
Normality was assessed with the use of qq-plots. Differ-
ences between groups (when the distribution was nor-
mal) were assesed with a one way analysis of variance
(ANOVA). Results were adjusted for the multiple compar-
isons with Tukey's HSD adjustment. Categorical data were
analysed using contingency tables with the Chi-Square
test. A five-step hierarchical regression of baseline group
differences in terms of demographic characteristics and
mean scores for the three main scales was conducted. At
first, the mean effects of disease, sex, age, education, activ-
ity and years since diagnosis were entered. In the second
step, the disease interactions with sex and age were added.
In the third step, the disease interactions with years since
diagnosis were entered. The fourth step involved adding
disease interactions with disease activity, and in the final
step, the disease and level of education interactions were
entered. At each step the "r2" and the "r2" change were
reported. A change in the "r2" was tested statistically. Dif-
ferences between groups and the general population for
quality of life were calculated with the independent sam-
ples t-test (two-tailed).
Results
Of 437 patients approached to participate in the study,
139 accepted the invitation (31.8% of all patients
invited). Of these, 64 patients had been previously diag-
nosed with IBD: 33 with UC and 31 with CD. Forty one
patients had been previously diagnosed with HCV and 34
with IBS. Twenty six percent of all invited patients with
IBD, 43.6% of all invited patients with HCV, and 32.4%
of all invited patients with IBS accepted the invitation to
participate in the study. Respondents and non-respond-
ents did not differ with respect to gender and public/pri-
vate health services user status. No other demographic
information was available for non-respondents as the
hospital ethics committee did not allow the authors to
collect any other data if a patient did not consent to par-
ticipate in the study.
The range of CDAI scores was between 0 and 319 and the
SCCAI range was 0 to 10. As regards treatments that may
influence psychological well being; six IBS patients were
on antidepressants. Ten HCV patients were receiving com-
bination therapy with interferon & ribavirin and seven
were taking antidepressants. Only one HCV patient was
taking both a combination therapy and an antidepressant.
In the IBD group, one CD patient and eight UC patients
Table 1: Gender and education in HCV, IBD and IBS participants
Disease HCV (n = 41) IBD (n = 64) IBS (n = 34) Total (n = 139)
Number of participants/percent N (%) N (%) N (%) N (%)
Gender* Male 21 (51) 25 (39) 8 (23) 54 (39)
Female 20 (49) 39 (61) 26 (77) 85 (61)
Education Primary 3 (7) 3 (5) 3 (9) 9 (7)
Secondary 22 (54) 29 (45) 13 (38) 64 (46)
Trade/TAFE 1 (2) 8 (12) 5 (15) 14 (10)
Tertiary 11 (27) 18 (28) 12 (35) 41 (29)
Not specified 4 (10) 6 (10) 1 (3) 11 (8)
* p ≤ 0.05Page 3 of 8
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UC were on oral prednisolone.
Demographic characteristics of participants with HCV, 
IBD and IBS
Overall, 61 percent of participants were female (See Table
1). The proportion of female to male participants in the
IBS group was significantly higher than in the IBD or the
HCV group (χ2 (2) = 6, p = 0.050). Participants did not
significantly differ in their level of education (χ2(6) =
5.48, p = 0.483).
The HCV group was significantly younger than the IBS
group and had significantly shorter period since the diag-
nosis than the IBD group (p ≤ 0.05) (See Table 2) whilst
the number of years with symptoms was similar in all the
three groups (p > 0.05).
Groups did not significantly differ in their disease activity
(Table 3).
Hierarchical regression showed significant demographic
differences on two scales: the SF-12 Physical and the
SCL90 PST (data not presented). Older participants
tended to have poorer physical quality of life than
younger participants (p = 0.014); those with HCV tended
to have poorer physical quality of life than those with UC
(p = 0.012); and those participants who had disease for a
longer time had better physical quality of life than those
reporting a briefer duration of disease (p = 0.016). More-
over, participants with CD tended to have poorer physical
quality of life than UC participants (p = 0.038), but their
physical quality of life increased with age (p = 0.037).
HCV participants with longer disease had poorer physical
quality of life (p = 0.050). Additionally, HCV participants
with the longer disease had higher (poorer) PST score
than those with the shorter disease (p = 0.032).
Differences in psychological profiles and quality of life 
between HCV, IBD and IBS participants
Groups did not significantly differ in mean scores for anx-
iety or depression as measured by the HADS nor in either
physical or mental components of quality of life (p >
0.05) (Table 4). Groups did not significantly differ on the
following subscales of the SCL90: the Interpersonal-Sensi-
tivity subscale, the Depression subscale, the Hostility sub-
scale, the Psychoticism subscale and the PSDI subscale,
either (p > 0.05).
The groups did, however, differ on the remaining 7 of 12
SCL90 subscales (Somatization, Obsessive-Compulsive,
Anxiety, Phobic Anxiety, Paranoid Ideation, GSI and PST).
The HCV group had the highest mean score on each of
these subscales of the SCL90, indicating higher psycholog-
ical morbidity in this group compared to both the IBS and
IBD groups. In particular, for the SCL90 Somatization,
Obsessive-Compulsive, Anxiety, Paranoid Ideation, GSI
and PST analysis, the HCV group had a higher score than
the IBD group (p = 0.05). For the SCL90 Phobic Anxiety
analysis, the HCV group had a higher score than the IBS
group (p = 0.048).
When we conducted an additional analysis (data not
shown) and compared the means on all the scales
between sexes in the whole group of patients, we observed
interestingly that male participants had higher scores on
the SCL90 Somatisation subscale (p = 0.021), the SCL90
Depression subscale (p = 0.042) and the SCL90 PST sub-
scale (p = 0.039) than female participants, indicating
higher levels of psychological co-morbidity in male as
compared to female participants.
Prevalence of anxiety and depression
Overall, 58 participants (42%) fulfilled anxiety criterion
for caseness (score > 7) and 26 participants (19%) ful-
filled depression criterion for caseness (score > 7) (See
Table 5). There was no significant difference between
groups in the prevalence of anxiety (χ2 (2) = 0.948, p =
0.623). However, there was a statistically significant dif-
ference in the prevalence of depression between the
groups (HCV = 34%, IBS = 15% and IBD = 11%, p =
0.009), with the HCV group having significantly higher
prevalence of depression than the IBD and IBS groups.
Quality of life comparisons between IBD, HCV and IBS 
groups and the general population
As the rate of psychological disorders in the three groups
was not high, comparisons with the normal population in
terms of quality of life were conducted to determine
whether, and by how much, the three disease groups dif-
fered from the healhy population.
Table 2: Age, years since diagnosis, years with symptoms in HCV, IBD and IBS participants
HCV Mean (SD) IBD Mean (SD) IBS Mean (SD) F p
Age 45(10)* 51 (15) 54 (13)* 3.793 0.023
Years since diagnosis 7 (4)* 14 (10)* 10 (9) 6.808 0.001
Years with symptoms 16 (9) 16 (11) 16 (13) 0.008 0.992
* differences significant at the level of p < 0.05Page 4 of 8
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ponents of quality of life were detected between each dis-
ease group and the general South Australian population
(Figure 1). The IBD group, the HCV group and the IBS
group each had poorer physical quality of life (means of
45.93, 43.41, and 43.11, respectively vs. 48.73; p = 0.032,
p = 0.003 & p = 0.004 respectively) and poorer mental
quality of life (means of 49.10, 44.59, and 46.36, respec-
tively vs. 52.3; p = 0.009, p = 0.000 & p = 0.000 respec-
tively) than the general South Australian population.
Discussion
This study is novel in that it compares psychosocial co-
morbidities in contemporaneous samples of patients with
IBD, IBS and HCV in Australia. However, it is important
to acknowledge that this study results need to be inter-
preted with caution due to the low participation rate of
only 32%. Unfortunately, due to the lack of full data on
non-participants, we are unable to speculate on the mag-
nitude of any bias and in which direction this bias may
fall. Whilst one may hypothesize that patients with more
severe psychological disease were less likely to participate,
it could equally be the case that less affected patients
thought the study of less relevance to them and declined.
Realistically, the low participation rate could only be
improved by incorporating these screening measures into
the routine clinical care of these patients, as there would
then be no issues of consent.
Whilst previous studies have reported a high prevalence of
psychological disorders in IBS [18] and only a moderate
level of these disorders in HCV [19], these data come from
different units at different time points. However, when
these patients are compared contemporaneously in the
one clinic, the current study clearly showed that patients
with HCV were the most depressed group, with 34% of
HCV patients suffering from depression compared with
only 15% of IBS and 11% of IBD patients.
Moreover, HCV patients were considerably more affected
by psychological disturbance than IBD patients on 6 sub-
scales of the SCL90 and more impaired than IBS patients
on one SCL90 subscale. Multiple regression showed that
demographic characteristics such as age, education, and
disease activity did not explain this difference, making it
less likely to be due simply to a selection bias of the par-
ticipants. Although, time since diagnosis might have
partly explained this result on the SCL90 PST (Positive
Symptom Total) subscale, as HCV participants with
longer disease duration had higher a mean PST score than
Table 3: Disease activity in HCV, IBD and IBS
Disease HCV (n = 41) IBD (n = 64) IBS (n = 34) Total (n = 139)
Number of participants (%) N (%) N (%) N (%) N (%)
Active disease 23 (56)1 23 (36) 18 (53) 64 (46)
Not active disease 18 (44) 41 (64) 14 (41) 73 (52)
Not specified 0 (0) 0 (0) 2 (6) 2 (2)
1 Active viral replication was used as a measure of disease activity in HCV
Table 4: Group differences on the HADS, SF-12 and SCL90 in HCV, IBD and IBS participants by one-way ANOVA
HCV Mean (SD) IBD Mean (SD) IBS Mean (SD) F p
HADS Anxiety 6.97 (4.83) 6.57 (3.44) 7.97 (2.92) 1.498 0.227
HADS Depression 5.36 (4.96) 4.07 (2.86) 4.29 (3.70) 1.513 0.224
SF12 Mental 44.59 (13.41) 49.10 (10.76) 46.36 (10.09) 2.024 0.136
SF12 Physical 43.41 (11.66) 45.93 (10.85) 43.11 (11.30) 0.974 0.380
Somatization 61.17 (12.90)* 55.35 (10.18)* 59.85 (8.23) 4.277 0.016
Obsessive-Compulsive 61.43 (11.59)* 56.48 (8.17)* 59.05 (9.77) 3.331 0.039
Interpersonal Sensitivity 60.43 (11.96) 55.43 (11.03) 57.52 (11.48) 2.397 0.095
Depression 62.26 (12.50) 58.04 (9.94) 59.99 (10.16) 1.909 0.152
Anxiety 57.63 (13.61)* 51.79 (9.74)* 56.82 (8.77) 4.462 0.013
Hostility 57.43 (11.98) 52.96 (9.86) 55.85 (11.00) 2.281 0.106
Phobic Anxiety 54.95 (11.60)* 51.54 (8.28) 49.79 (7.96)* 3.073 0.050
Paranoid Ideation 56.58 (11.99)* 50.73 (10.18)* 51.88 (11.86) 3.568 0.031
Psychoticism 58.24 (10.58) 54.46 (8.97) 56.23 (10.18) 1.878 0.157
GSI 62.00 (12.22)* 55.95 (9.66)* 59.94 (9.75) 4.450 0.013
PST 60.92 (11.34)* 55.93 (9.51)* 58.85 (9.33) 3.201 0.044
PSDI 57.97 (9.78) 54.29 (9.80) 56.61 (8.36) 1.997 0.140
* differences significant at the level of p < 0.05Page 5 of 8
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group was more homogenous than the remaining groups
in time since diagnosis as indicated by the narrower
spread around the mean in this variable. The fact that IBD
patients were the group least affected by psychological
problems compared to IBS and HCV participants indi-
cated that the overt physical morbidity of an inflamma-
tory illness did not directly drive psychological morbidity
in these patients.
Although, in our group, HCV patients experience more
psychological problems than IBS and IBD participants,
their prevalence of depression was comparable to the
reported average (30%) for other chronic diseases [20],
whereas in our IBS and IBD groups, the prevalence of
depression was significantly lower than usually reported
[4,21-23]. The prevalence of anxiety in all three groups
(42%), on the other hand, was much elevated compared
with the usually reported 20% prevalence in chronic dis-
eases [24]. In comparison with other studies on preva-
lence of anxiety in HCV, IBD and IBS, the current
prevalence seems elevated for HCV and IBD participants
[23,25], however it is consistent with existing data for IBS
[26].
The fact that 56% of IBS participants and 36% of IBD par-
ticipants had active disease may contribute to this finding,
as frequent visits to toilets and, in consequence, a disrup-
tion to normal functioning may lead to anxiety. In HCV,
however, the cause is not as clear but may, in part be
related to some or all of the following factors: disease
stigma; frequent coexistent drug and alcohol addiction;
and co-occurrence of HCV with other diseases such as
AIDS [19]. In addition, the psychological status of HCV
patients is also known to be dependant on whether they
are aware of their HCV positivity [27], with those aware of
their diagnosis being more impaired than those unaware,
suggesting the influence of cognitive factors in addition to
"medical" or disease and treatment related issues. Another
factor contributing to the finding of high rates of anxiety
and depression in HCV may be psychological side-effects
of treatment with Interferon-Ribavirin [28]. In particular,
Interferon is thought to affect pathways that are involved
in the aetiology of depression [29]; however, the strength
of the association between Interferon and depression is
disputed as the available studies do not commonly use
validated measures of depression [30].
Another hypothesis is that the actual virus may directly
effect brain functions [31] and be capable of infecting the
central nervous system causing neurological damage. It
has been reported that this neurological damage may
manifest itself through cognitive impairment in the
domains of attention, concentration and information
processing speed [32]. It is unclear whether this may also
lead to depression or anxiety, however, this possibility
should not be ignored.
Finally, it is important to acknowledge that the psycholog-
ical screening questionnaires used in the present study
only indicate the likelihood of anxiety and depression,
and ideally, definite cases need to be formally diagnosed
by a mental health specialist using a structured psychiatric
interview based on the Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV) classification [12]. For this
reason, the prevalence of psychological problems noted in
this study should be interpreted with caution. Future stud-
ies would benefit from incorporating structured psychiat-
ric interviews to confirm diagnoses.
Conclusion
Based on our data, patients with HCV should be screened
for depression, and all three groups for anxiety, as recog-
nition and treatment of these psychological co-morbidi-
ties has the potential to improve patient outcomes. This
could be done with the use of free and simple screening
measures such as the Depression, Anxiety and Stress Scale
(DASS). Unquestionably, given the high prevalence of
anxiety we have reported, future studies should focus on
interventions targeting anxiety which appears to be an
unrecognised problem in patients with gastrointestinal
and hepatologic disorders. The role of psychological co-
morbidities, and treatment of them, on clinical outcomes
deserves further study.
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